CHRS250516P2000
- 0.00
- 0.000.00%
Coherus BioSciences Newsroom
Coherus Biosciences: Data From Ongoing Phase 1 Clinical Trial Evaluating CHS-114 Shows Clinical Efficacy And Proof Of Mechanism In HNSCC In Combination With Toripalimab
Coherus BioSciences Price Target Cut to $1.05/Share From $1.50 by UBS
Coherus BioSciences Is Maintained at Neutral by UBS
Coherus BioSciences Analyst Ratings
New Analyst Forecast: $CHRS Given $1.05 Price Target
Coherus Biosciences CCO Resigns After UDENYCA Divestiture
Sector Update: Health Care
Coherus BioSciences Completes Sale of Udenyca Franchise to Intas Pharmaceuticals for Up to $558.4 Million
Express News | Accord Biopharma, Inc. Announces Completion of Udenyca® (Pegfilgrastim-Cbqv) Franchise Acquisition From Coherus BioSciences, Inc., Expanding U.S. Biosimilar Portfolio
Express News | Coherus Completes Strategic Transformation With Successful Divestiture of Udenyca® Franchise
Coherus Completes Strategic Transformation With Successful Divestiture of UDENYCA Franchise
Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 27%
Express News | Coherus To Present Data From Phase 1 Dose Expansion Study Of CHS-114 At 2025 American Association For Cancer Research Annual Meeting
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Statutory Earnings May Not Be The Best Way To Understand Coherus BioSciences' (NASDAQ:CHRS) True Position
We Believe Coherus BioSciences' (NASDAQ:CHRS) Earnings Are A Poor Guide For Its Profitability
Barclays Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7
Coherus BioSciences | 10-K: FY2024 Annual Report